JPRN-jRCT1080222219未知Unknown
esina tablets special drug use surveillance Type 2 diabetes mellitus: Combination therapy with sulfonylurea
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 1,000 人开始时间: 2013年9月10日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who did not adequately respond to the following treatment
- •Treatment with sulfonylurea in addition to diet therapy and exercise therapy
排除标准
- •Patients contraindicated for Nesina
- •(1) Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus [these patients require prompt adjustment of hyperglycemia by fluid infusion and insulin, and hence use of Nesina is not appropriate.]
- •(2) Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury [blood glucose control by insulin injection is desirable for these patients, and hence use of Nesina is not appropriate.]
- •(3) Patients with a history of hypersensitivity to any ingredient of Nesina
研究者
相似试验
未知
Unknown
esina tablets special drug use surveillance Type 2 diabetes mellitus: Combination therapy with thiazolidinedionesJPRN-jRCT1080222218TAKEDA PHARMACEUTICAL COMPANY LTD.1,000
已完成
Unknown
Alogliptin tablets special drug use surveillance: Mild type 2 diabetes mellitusType 2 diabetes mellitusJPRN-jRCT1080222234Takeda Pharmaceutical Company Limited19,192
未知
Unknown
Azilva Tablets special drug use surveillance Hypertension complicated by diabetesHypertensionJPRN-jRCT1080222416TAKEDA PHARMACEUTICAL COMPANY LTD.300
进行中（未招募）
不适用
Protocol Number; CLCZ696B1401Chronic Heart FailureJPRN-jRCT2031200432Sugimoto Toshiya660
已完成
Unknown
Alogliptin tablets special drug use surveillance Type 2 diabetes mellitus: monotherapy/combination therapy with alpha-GIJPRN-jRCT1080222203Takeda Pharmaceutical Company Limited3,317